COMPASS Pathways (NASDAQ:CMPS - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.62) per share for the quarter. Investors interested in registering for the company's conference call can do so using this link.
COMPASS Pathways Trading Down 7.3 %
COMPASS Pathways stock traded down $0.33 during trading on Friday, hitting $4.21. The company's stock had a trading volume of 1,850,673 shares, compared to its average volume of 1,307,498. COMPASS Pathways has a 1-year low of $3.16 and a 1-year high of $12.75. The stock's fifty day moving average is $4.09 and its 200 day moving average is $5.39. The stock has a market capitalization of $288.05 million, a price-to-earnings ratio of -1.91 and a beta of 2.28. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91.
Wall Street Analysts Forecast Growth
CMPS has been the topic of several recent research reports. Maxim Group reduced their price target on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. HC Wainwright reduced their price target on COMPASS Pathways from $60.00 to $45.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $30.60.
Get Our Latest Analysis on CMPS
About COMPASS Pathways
(
Get Free Report)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Read More
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
